comparemela.com

Latest Breaking News On - Julia neugebauer - Page 15 : comparemela.com

MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023

EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023 14.06.2023 / 08:39. | June 14, 2023

United statesNew yorkThomas biegiTim demuthJean paul kressJulia neugebauerJohn mascarenhasEamonn nolanGabriela hobbsAdult leukemia programLeukemia service at massachusettsTisch cancer institute at mount sinaiProfessor of medicine at harvard medical schoolConstellation pharmaceuticals incExchange commissionHost virtual investor call

MorphoSys AG Reports Outcome of Annual General Meeting 2023

EQS-News: MorphoSys AG / Key word(s): AGM/EGMMorphoSys AG Reports Outcome of Annual General Meeting 2023 17.05.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 17, 2023 MorphoSys AG Reports Outcome of Annual General Meeting 2023.

United statesMichael brosnanThomas biegiGeorge golumbeskiJulia neugebauerEamonn nolanJean paul kressArticles of associationDistribution servicesExchange commissionAnnual general meetingSupervisory boardsManagement boardSupervisory boardAuthorized capitalConditional capital

MorphoSys AG Reports Outcome of Annual General Meeting 2023

EQS-News: MorphoSys AG / Key word: AGM/EGM MorphoSys AG Reports Outcome of Annual General Meeting 2023 17.05.2023 / 22:01 CET/CEST The issuer is solely responsible for the. | May 17, 2023

United statesGeorge golumbeskiEamonn nolanMichael brosnanThomas biegiJulia neugebauerJean paul kressArticles of associationExchange commissionAnnual general meetingSupervisory boardsManagement boardSupervisory boardAuthorized capitalConditional capitalRemuneration report

MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings

EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings 11.05.2023 / 18:39. | May 11, 2023

United statesJulia neugebauerEamonn nolanTim demuthThomas biegiConstellation pharmaceuticals incEuropean hematology associationAmerican society of hematology annual meetingXencor incAmerican society of clinical oncologyDrug administrationExchange commissionDevelopment officerAmerican association for cancer research annual meetingSys highlights potentialLate stage oncology pipeline

MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annu

EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings 11.05.2023 / 18:39 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, May 11, 2023 M.

United statesEamonn nolanThomas biegiJulia neugebauerTim demuthXencor incDrug administrationAmerican society of clinical oncologyDistribution servicesDevelopment officerExchange commissionEuropean hematology associationConstellation pharmaceuticals incAmerican association for cancer research annual meetingAmerican society of hematology annual meetingSys highlights potential

vimarsana © 2020. All Rights Reserved.